14.12.2009 Holzgerlingen – A consortium of leading life-science venture
capital funds invests € 18.5 million in the German medical diagnostics
company Curetis AG. This financing will enable Curetis to complete
development of its innovative diagnostic products through to market entry.
Founded in August 2007, Curetis is a molecular diagnostic company focusing on
the development of tools to test for severe infectious diseases. The new financing
of € 18.5 million is provided by an international consortium, composed of four
partners – including the existing investor aeris CAPITAL, which seeded Curetis
with € 1.4 million in 2008. New syndicate members include: LSP (Life Sciences
Partners), BioMedPartners as well as the ERP-Startfonds of the KfW
Bankengruppe. MedVenture Partners GmbH supported Curetis in concluding the
transaction.

Curetis is developing universal molecular diagnostic solutions, initially focusing on
severe bacterial infections; i.e. pneumonia. Given that globally, over 25 million
people are diagnosed each year with pneumonia, there is a strong demand for
new devices identifying timely and cost-effective treatment options.

More information:

http://www.curetis.com/press/archive/20091203CuretisPIFinRound2engl.pdf

Contact:

Curetis AG
Max-Eyth-Straße 42
D-71088 Holzgerlingen
Tel: +49 (0)7031 49195-10
Fax: +49 (0)7031 49195-19
www.curetis.com